SCHEMBL1038876

SCHEMBL1038876

COc1cc(Nc2ncc(F)c(Nc3ccc(NS(=O)(=O)Cc4ccccc4)cc3)n2)cc(OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 9/20 0.56
ITK Q08881 5/20 0.54
EGFR P00533 4/20 0.54
ADORA3 P0DMS8 2/20 0.51
TYRO3 Q06418 2/20 0.51
CYP17A1 P05093 1/20 0.49
AURKA O14965 6/20 0.49
PLK4 O00444 3/20 0.49
PDPK1 O15530 3/20 0.49
JAK2 O60674 3/20 0.49
PRKD3 O94806 3/20 0.49
NTRK1 P04629 3/20 0.49
INSR P06213 3/20 0.49
LCK P06239 3/20 0.49
FYN P06241 3/20 0.49
CSF1R P07333 3/20 0.49
IGF1R P08069 3/20 0.49
ROS1 P08922 3/20 0.49
FGFR1 P11362 3/20 0.49
FLT1 P17948 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1035950 0.90 PTK2 (0.54) SYKITKEGFRADORA3TYRO3
SCHEMBL1221693 0.89 SYK (0.64) SYKITKEGFRADORA3TYRO3
SCHEMBL1035455 0.86 SYK (0.58) SYKITKEGFRADORA3TYRO3
SCHEMBL1040295 0.85 SYK (0.55) SYKITKEGFRADORA3TYRO3
SCHEMBL1222410 0.84 SYK (0.58) SYKITKEGFRADORA3TYRO3
SCHEMBL12894667 0.84 SYK (0.62) SYKITKEGFRADORA3TYRO3
SCHEMBL1222113 0.83 EGFR (0.68) SYKITKEGFRADORA3TYRO3
SCHEMBL1222402 0.83 SYK (0.57) SYKITKEGFRADORA3TYRO3
SCHEMBL1221660 0.81 EGFR (0.61) SYKITKEGFRADORA3TYRO3
SCHEMBL1222117 0.81 SYK (0.57) SYKITKEGFRADORA3TYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US claimed
EP-2276747-A1 SULFONAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2011-01-26 EP claimed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO claimed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
EP-2276747-A1 SULFONAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2011-01-26 EP disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS ZAP70, SYK, LCK SYK 2/4885ITK 429/4885EGFR 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.